MARC details
000 -LEADER |
fixed length control field |
02847nam a22003257a 4500 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
220221s20222022 xxu||||| |||| 00| 0 eng d |
024 ## - OTHER STANDARD IDENTIFIER |
Standard number or code |
10.2337/db21-0590 [doi] |
024 ## - OTHER STANDARD IDENTIFIER |
Standard number or code |
140947 [pii] |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
Ovid MEDLINE(R) |
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
PMID |
35061024 |
245 ## - TITLE STATEMENT |
Title |
Islet Autoimmunity is Highly Prevalent and Associated With Diminished beta-Cell Function in Patients With Type 2 Diabetes in the Grade Study. |
251 ## - Source |
Source |
Diabetes. 2022 Jan 21 |
252 ## - Abbreviated Source |
Abbreviated source |
Diabetes. 2022 Jan 21 |
253 ## - Journal Name |
Journal name |
Diabetes |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Year |
2022 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Manufacturer |
FY2022 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Publication date |
2022 Jan 21 |
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
Publication status |
aheadofprint |
266 ## - Date added to catalog |
Date added to catalog |
2022-02-21 |
501 ## - WITH NOTE |
Local holdings |
Available online from MWHC library: 1995 - present (after 3 months), Available in print through MWHC library: 1999 - 2006 |
520 ## - SUMMARY, ETC. |
Abstract |
Islet autoimmunity may contribute to beta-cell dysfunction in type 2 diabetes (T2D). Its prevalence and clinical significance have not been rigorously determined. In this ancillary study to the Glycemia Reduction Approaches in Diabetes-A Comparative Effectiveness (GRADE) Study, we investigated the prevalence of cellular and humoral islet autoimmunity in patients with T2D duration 4.0+/-3.0 y, HbA1c 7.5+/-0.5% on metformin alone. We measured T cell autoreactivity against islet proteins, islet autoantibodies against GAD65, IA2, ZnT8, and beta-cell function. Cellular islet autoimmunity was present in 41.3%, humoral islet autoimmunity in 13.5%, and both in 5.3%. beta-cell function calculated as iAUC-CG and DELTAC-peptide(0- 30)/DELTAglucose(0-30) from an oral glucose tolerance test was lower among T cell-positives (T+) than T cell-negatives (T-) using two different adjustments for insulin sensitivity (iAUC-CG: 13.2% [95% CI 0.3, 24.4%] or 11.4% [95% CI 0.4, 21.2%] lower; DELTAC-peptide(0-30)/DELTAglucose(0-30)) 19% [95% CI 3.1, 32.3%] or 17.7% [95% CI 2.6, 30.5%] lower). T+ patients had 17% higher HbA1c (95% CI 0.07, 0.28) and 7.7 mg/dL higher fasting plasma glucose levels (95% CI 0.2,15.3) than T- patients. We conclude that islet autoimmunity is much more prevalent in T2D patients than previously reported. T cell-mediated autoimmunity is associated with diminished beta-cell function and worse glycemic control. Copyright (c) 2022 by the American Diabetes Association. |
546 ## - LANGUAGE NOTE |
Language note |
English |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
IN PROCESS -- NOT YET INDEXED |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
Institution |
MedStar Medical Group |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Journal Article |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Park, Jean Y |
790 ## - Authors |
All authors |
Balasubramanyam A, Brooks-Worrell B, Cohen RM, Desouza C, Florez HJ, GRADE Beta-cell Ancillary Study Network, Hampe CS, Hattery EG, Johnson ML, Kahn SE, Larkin ME, Mather KJ, Palmer JP, Palomino B, Park JY, Rasouli N, Shojaie A, Utzschneider K, Valencia WM, Younes N, Zangeneh SZ |
856 ## - ELECTRONIC LOCATION AND ACCESS |
DOI |
<a href="https://dx.doi.org/10.2337/db21-0590">https://dx.doi.org/10.2337/db21-0590</a> |
Public note |
https://dx.doi.org/10.2337/db21-0590 |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Koha item type |
Journal Article |
Item type description |
Article |